Cornell University

About: Cornell University is a education organization based out in Ithaca, New York, United States. It is known for research contribution in the topics: Population & Gene. The organization has 102246 authors who have published 235546 publications receiving 12283673 citations. The organization is also known as: Cornell & CUI.

Computational Frameworks for the Fast Fourier Transform

Abstract: 1. The Radix-2 Frameworks. Matrix Notation and Algorithms The FFT Idea The Cooley-Tukey Factorization Weight and Butterfly Computations Bit Reversal and Transposition The Cooley-Tukey Framework The Stockham Autosort Frameworks The Pease Framework Decimation in Frequency and Inverse FFTs 2. General Radix Frameworks. The General Radix Ideas Index Reversal and Transposition Mixed-Radix Factorizations Radix-4 and Radix-8 Frameworks The Split-Radix Frameworks 3. High Performance Frameworks. The Multiple DFT Problem Matrix Transposition The Large Single-Vector FFT Problem Multi-Dimensional FFT Problem Distributed Memory FFTs Shared Memory FFTs 4. Selected Topics. Prime Factor FFTs Convolution FFTs of Real Data Cosine and Sine Transforms Fast Poisson Solvers Bibliography Index.

Climate-smart soils

Abstract: Soils are integral to the function of all terrestrial ecosystems and to food and fibre production. An overlooked aspect of soils is their potential to mitigate greenhouse gas emissions. Although proven practices exist, the implementation of soil-based greenhouse gas mitigation activities are at an early stage and accurately quantifying emissions and reductions remains a substantial challenge. Emerging research and information technology developments provide the potential for a broader inclusion of soils in greenhouse gas policies. Here we highlight 'state of the art' soil greenhouse gas research, summarize mitigation practices and potentials, identify gaps in data and understanding and suggest ways to close such gaps through new research, technology and collaboration.

Universal robotic gripper based on the jamming of granular material

Abstract: Gripping and holding of objects are key tasks for robotic manipulators. The development of universal grippers able to pick up unfamiliar objects of widely varying shape and surface properties remains, however, challenging. Most current designs are based on the multifingered hand, but this approach introduces hardware and software complexities. These include large numbers of controllable joints, the need for force sensing if objects are to be handled securely without crushing them, and the computational overhead to decide how much stress each finger should apply and where. Here we demonstrate a completely different approach to a universal gripper. Individual fingers are replaced by a single mass of granular material that, when pressed onto a target object, flows around it and conforms to its shape. Upon application of a vacuum the granular material contracts and hardens quickly to pinch and hold the object without requiring sensory feedback. We find that volume changes of less than 0.5% suffice to grip objects reliably and hold them with forces exceeding many times their weight. We show that the operating principle is the ability of granular materials to transition between an unjammed, deformable state and a jammed state with solid-like rigidity. We delineate three separate mechanisms, friction, suction, and interlocking, that contribute to the gripping force. Using a simple model we relate each of them to the mechanical strength of the jammed state. This advance opens up new possibilities for the design of simple, yet highly adaptive systems that excel at fast gripping of complex objects.

High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor.

Abstract: Nerve growth factor (NGF) interacts with two different low-affinity receptors that can be distinguished by affinity crosslinking Reconstitution experiments by membrane fusion and transient transfection into heterologous cells indicate that high-affinity NGF binding requires coexpression and binding to both the low-affinity NGF receptor and the tyrosine kinase trk gene product These studies reveal a new growth factor receptor-mediated mechanism of cellular differentiation involving trk and the low-affinity NGF receptor

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Abstract: A b s t r ac t Background Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. Methods We conducted two prospective phase 2 trials in which patients with atypical hemo lytic–uremic syndrome who were 12 years of age or older received eculizumab for 26 weeks and during long-term extension phases. Patients with low platelet counts and renal damage (in trial 1) and those with renal damage but no decrease in the platelet count of more than 25% for at least 8 weeks during plasma exchange or infu sion (in trial 2) were recruited. The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event–free status (no de crease in the platelet count of >25%, no plasma exchange or infusion, and no initia tion of dialysis) (in trial 2). Results A total of 37 patients (17 in trial 1 and 20 in trial 2) received eculizumab for a median of 64 and 62 weeks, respectively. Eculizumab resulted in increases in the platelet count; in trial 1, the mean increase in the count from baseline to week 26 was 73×10 9 per liter (P<0.001). In trial 2, 80% of the patients had thrombotic microangiopathy event–free status. Eculizumab was associated with significant improvement in all secondary end points, with continuous, time-dependent increases in the estimated glomerular filtration rate (GFR). In trial 1, dialysis was discontinued in 4 of 5 patients. Earlier intervention with eculiz umab was associated with significantly greater improvement in the estimated GFR. Eculizumab was also associated with improvement in healthrelated quality of life. No cumulative toxicity of therapy or serious infection-related adverse events, including meningococcal infections, were observed through the exten